www.stirlingproducts.net
Stirling Products (ASX:STI) is a manufacturer and marketer of proprietary and/or patented pharmaceutical products and natural health products for its own interests as well as on a contractual basis for third parties. Strategically, Stirling Products is positioned to capitalise on the rapidly changing conditions within the global pharmaceutical and health markets.
The Stirling Products corporate headquarters are in Sydney, Australia and its North American pharmaceutical manufacturing operations are based on Cape Breton, Nova Scotia, Canada.
Stirling operates through three main business units each managed by proven industry specialist managers:
- Pharmaceutical & Healthcare
- Research & Development
- Animal Products
Stirling Products issued with patent for obesity drug compound
Australian pharmaceutical and healthcare group, Stirling Products (ASX:STI) has been issued with a full patent and publication of its R-Salbutamol obesity drug candidate by the Australian Patents Office.
The Patent is for use of the Company’s R-Salbutamol as a method of decreasing fat deposits and is valid until 12 November 2024.
Salbutamol has been safely used in humans in the treatment of respiratory disease for over 30 years, and in its purified form, R-Salbutamol, for over 15 years. Its application to obesity does not require any drug discovery work but rather the re-purposing of an existing approved drug, which is a common practice within the pharmaceutical industry.
The company had earlier advised that investigations of R-Salbutamol in its application as an obesity drug have been favourable.
Peter Boonen, managing director of Stirling Products said the proof of concept conducted by the company in beagle dogs had achieved weight loss results of two per cent per week, "which is a good indicator of the potential in humans."
Stirling will seek a major industry partner for further development of the obesity drug candidate at an appropriate time.


















